The collaboration will aim to seek innovative and pioneering eye cancer treatment solutions, and also allow for genetic, molecular and cellular analysis
A Memorandum of Understanding (MoU) was signed between the LV Prasad Eye Institute (LVPEI), India and the Antonio Champalimaud Foundation, Lisbon, Portugal for advancing the treatment of eye cancer. The collaboration will aim to seek innovative and pioneering eye cancer treatment solutions, and also allow for genetic, molecular and cellular analysis. Champalimaud Centre for the Unknown’s (CCU) cancer programme is the most advanced in the world.
The formal MoU was signed by Dr Gullapalli N Rao, Founder-Chair, LVPEI and Dr Leonor Beleza, President, Antonio Champalimaud Foundation. Also present were Joao Botelho, Vice President and Prof Antonio Parreira, Clinical Director, Champalimaud Foundation, and Dr S Shivaji, Director of Research, LVPEI.
Specialised eye cancer treatment is a highly advanced subspecialty clinical eye care service provided at the LVPEI. The Institute’s ‘Operation Eyesight Institute for Eye Cancer’ is led by a dedicated and experienced team that provides state-of-the-art care for eye cancer of all types.
The goal of this programme is to understand and prevent cancer. This is particularly critical for India, as eye cancer (Retinoblastoma) is most common in children. This collaboration will hopefully bring new insights and therapeutic approaches to the problem of eye cancer.